Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Cleveland biopharmaceutical company Athersys Inc. (NASDAQ:ATHX) is seeking to expand the market for its main stem cell product. Athersys announced Wednesday morning, Jan. 18, that it will work with a “global leader in the animal health business segment” to develop cell therapy technology for use in a “non-disclosed animal health area.
Click here to read the complete article.
Originally published January 18, 2017.